Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023GlobeNewsWire • 09/06/23
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/03/23
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/20/23
Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care MedicineGlobeNewsWire • 06/28/23
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPDGlobeNewsWire • 06/27/23
Verona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial PositionSeeking Alpha • 05/28/23
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/23
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023GlobeNewsWire • 05/02/23
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 04/25/23
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh AirSeeking Alpha • 04/16/23
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPDGlobeNewsWire • 04/10/23